What moved it
How to read these marks1 finding · 1 compound · by evidence strength. No dose is advised.
PANSS positive subscale score
Findings drawn, by strength
1finding · 1 compound
- Very limited1
Keys
← → round a ring↑ ↓ out and inEnter selecte the outer ringf fit to view+ − zoomEsc clearclick a node to select it
Not pooled · no summary effect · point at a mark · Tab, then the arrow keys
Reported to move it1 finding
- L-theanineMoved: lowersEvidence: Very limitedPaper: PMID 212085862011
- Who
- Chronic schizophrenia or schizoaffective disorder (DSM-IV); antipsychotic treatment continued in both arms as background; 8-week 2-center trial; PANSS 3-dimensional model
- Dose studied
- L-theanine 400 mg/d added to ongoing antipsychotic
Compared with placebo, L-theanine augmentation was associated with reduction of anxiety (P = .015; measured by the HARS scale) and positive (P = .009) and general psychopathology (P < .001) scores (measured by the PANSS 3-dimensional model).”
Quoted verbatim from L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center study.RCT · 8 weeksPermalink
No row matches these filters.
How it is measured
Sum of the seven positive scale items (P1 to P7: delusions, conceptual disorganisation, hallucinatory behaviour, excitement, grandiosity, suspiciousness and hostility) of the PANSS (Kay, Fiszbein and Opler 1987), each rated 1 to 7, summed to 7 to 49; higher is worse.
Measured, with no finding
1 measurement
Show what was measuredHide what was measured
PANSS positive subscale score
no effect
Not recorded as a finding: Agentless passive covering four outcomes in one sentence and never naming the compound.
No significant within- or between-group changes were observed for PANSS positive, SANS, CDRS, or MATRICS composite scores (Table 2).
PMID 28289280 · one of two readings recorded this
Papers about it
As an endpoint2
Show the papersHide the papers
Biochemical, physiological and clinical effects of l-methylfolate in schizophrenia: a randomized controlled trial.
Molecular psychiatry2018PMID 28289280Via: named in the paper, as read
L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center study.
The Journal of clinical psychiatry2011PMID 21208586Via: named in the paper, as read
Newest
Biochemical, physiological and clinical effects of l-methylfolate in schizophrenia: a randomized controlled trial.
Molecular psychiatry2018PMID 28289280As an endpoint
L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center study.
The Journal of clinical psychiatry2011PMID 21208586As an endpoint